tbuckley/cabot-search huggingface dataset:
Electronic patient-reported data capture as the foundation of a learning health care system
Authors: A. P. Abernethy, S. Y. Zafar, R. Coeytaux, K. Rowe, J. L. Wheeler, H. K. Lyerly
Journal: Journal of Clinical Oncology (2009)

6522 Background: In a “learning healthcare system” clinical decisions are supported by accurate information delivered at point of care; information gathered today iteratively informs future care and research. Methods: Customized software on wireless tablet personal computers presented a review of systems (ROS) instrument, validated research surveys (e.g., quality of life [QOL]), and a satisfaction survey, tailored by user. The system was piloted in the Duke Cancer Clinics and affiliated hospitals. We previously demonstrated equivalence of electronic and paper survey data. We conducted a series of studies using similar procedures to evaluate feasibility, acceptability, and utility. Results: First, we assessed the ability to collect ROS data at point of care to inform the clinic visit for participating breast (n = 65), gastrointestinal (n = 113), and lung (n = 97) cancer patients. Duke physicians reported that the system's clinical reports informed care and increased dictation efficiency. Second, we assessed patient satisfaction in the breast cancer cohort. Participants found the computers easy to read (94%), navigate (99%), and use (98%); the system helped 74% remember forgotten concerns to report to their clinician. Third, we assessed whether these data could contribute to current research. If the patient was on another clinical trial, PRO data (e.g., pain, QOL) were delivered to the investigator for research purposes in real time; data governance rules provided assurance to investigators. Fourth, we identified whether the PRO data could inform future research directions. Symptoms monitored longitudinally in aggregate uncovered unmet needs. Sexual distress was an underserved concern; intervention studies were initiated. Warehoused PRO data were integrated with clinical trials, genomic, biomarker, radiology, and administrative datasets for analyses. The approach has been scaled to 4 clinics and 3 hospitals. Conclusions: An integrated, real-time, electronic data capture system that interdigitates PROs with clinical and other data allows creation of a learning oncology environment that continuously improves care and research. Advantages include: patient-centeredness, description of the PRO phenotype, interoperability, and interface with caBIG infrastructure. No significant financial relationships to disclose.
The effect of passive smoking on body height, body weight, peak expiratory flow rate and motor skills in children
Authors: Ivan Pavic, Pero Pavic, Slavica Dodig, Jasna Cepin-Bogovic, Martina Krmek
Journal: European Respiratory Journal (2012)

Passive smoking is strongly linked to a range of adverse child health outcome. The objectives of the present study were to assess: 1) proportion of school children passively exposed to cigarette smoke; 2) the impact of passive smoking on body height and body weight; 3) the influence of passive smoking on peak expiratory flow rate (PEFR); and 4) on the motor skills in school children.  This prospective study included 133 children, 66 males and 67 females, aged from 11 to 14 years. Subjects were divided in two groups depending on parental smoking habits: Group I – children of smoking parents who smoke 10 or more cigarettes per day (88/133=66%) and Group II – children of non-smoking parents (45/133=34%). For the assessment of motor skills 6-minute run test (F-6 test) was used.  88/133 (66%) children have been exposed to passive smoking, while 45/133 (34%) children came from families of non-smoking parents. There was no statistically significant difference in either height or in weight. The PEFR (L/min) values for Group I were statistically lower [320 (300-370)] than in control group of children [380(347-405] (P =   Children of smoking parents have statistically significant lower grade of motor skills and statistically significant lower PEFR value than children of non-smoking parents. Public health preventive actions should go toward minimizing the exposure of children to passive smoking by counseling the smoking parents that quitting smoking provides enormous health benefits not only to them but also to their children.
Current Status of Oral Anticancer Drugs in Japan
Authors: Yasuhiro Fujiwara
Journal: Journal of Clinical Oncology (1999)

Article Tools Correspondence Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1999.17.10.3362 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 10506642 Current Status of Oral Anticancer Drugs in Japan Yasuhiro FujiwaraxYasuhiro FujiwaraSearch for articles by this author Show More Pharmaceuticals and Medical Devices Evaluation Center, National Institute of Health Sciences, Ministry of Health and Welfare, Tokyo, Japan https://doi.org/10.1200/JCO.1999.17.10.3362 First Page Full Text PDF Figures and Tables © 1999 by American Society of Clinical Oncology
Immune status at pre-treatment impacts on progression-free survival of metastatic colorectal cancer patients treated with first-line chemotherapy
Authors: Kohei Tada, Shigehisa Kitano, Hirokazu Shoji, Takashi Nishimura, Yasuhiro Shimada, Kengo Nagashima, Yoshitaka Honma, Satoru Iwasa, Natsuko Okita, Atsuo Takashima, Ken Kato, Yasuhide Yamada, Naoyuki Katayama, Narikazu Boku, Tetsuya Hamaguchi, Yuji Heike
Journal: Journal for ImmunoTherapy of Cancer (2015)

Meeting abstracts Immunological status in surgically resected specimens affects the outcome of ‘operable’ colorectal cancer patients. For example, a high number of tumor infiltrating lymphocytes, CD3+ cells, CD8+ cells, or CD45RO+ cells in a tumor is associated with improved prognosis. However
TAPSE as a prognostic factor in hemodinamically stable pulmonary embolism
Authors: J.L. Lobo, P. Sobradillo, I. Obieta-Fresnedo, A. Rivas, R. Valle, C. Navarro, D. Jimenez
Journal: European Respiratory Journal (2011)

Introduccion:  Right Ventricular Dysfunction (RVD) is a predictor of mortality in Pulmonary Embolism. The reproducibility of classic parameters is low. The TAPSE is easier and more reproducible.   Aim:  To asses whether TAPSE has prognostic value in patients with PE.   Methods:  PROTECT is a multicentric study of patients with hemodynamically stable PE; evolution data were gathered through 30 days. Echocardiography in the first 48 hours. RVD criteria: 1) RVEDD >30; 2) RV/LV >1.0; 3) hypokinesia subjectively evaluated; or 4) TR jet >2.8 m/s. Statistical analysis with SPSS (v. 15). Means were compared with T-Student for quantitative variables; Chi-square for qualitative. OR and corresponding 95CI calculated with univariate logistic regression. Multivariate analysis could not be carried out due to the low number of events.   Results:  The study included 630 patients. Global mortality was 3,8%, and mortality due to PE was 0,8%. TAPSE could be determined in 91,7% of the patients. Only 16% showed an abnormal TAPSE (≤15). Univariate analysis for 30-day mortality is shown in the table.   Conclusions:  1. The probability of dying of PE in the first month is multiplied by more than 20 in patients with a TAPSE ≤ 15. 2. The strength of the association seems clearly superior to the classic echocardiographic parameters of right ventricle dysfunction.
Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): Planned final analysis (FA) of COU-AA-301, a randomized, double-blind, placebo-controlled, phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel.
Authors: H. I. Scher, G. Heller, A. Molina, T. S. Kheoh, G. Attard, J. Moreira, S. K. Sandhu, C. Parker, C. Logothetis, R. T. McCormack, K. Fizazi, A. Anand, D. C. Danila, M. Fleisher, D. Olmos, C. M. Haqq, J. S. De Bono
Journal: Journal of Clinical Oncology (2011)

LBA4517 Background: A preplanned interim analysis of COU-AA-301 showed that AA, a selective androgen biosynthesis (CYP17) inhibitor, significantly improves OS in mCRPC. This is the first phase III study to prospectively assess CTC as a surrogate biomarker as part of a regulatory qualification process, here using updated OS data. Methods: 1,195 patients (pts) with mCRPC post docetaxel were randomized 2:1 to AA (1 g QD) + P (5 mg BID) (n = 797) or placebo + P (n = 398). CTCs (screening and baseline [BL]; post BL at weeks 4, 8 and 12) were enumerated (cells/7.5 mL) at MSKCC and The ICR using CellSearch and analyzed with other prognostic covariates as dichotomous and continuous variables using updated OS data at 775 events (prior to crossover from placebo to AA). CTC (as part of a biomarker panel - LDH, PSA, Hg, AlkPhos) was examined as a surrogate for OS. Multivariate (Cox model) analyses were conducted. Results: At median follow up (FU) of 20.2 mo, the difference in median OS between the 2 groups improved from 3.9 to 4.6 mo (AA 15.8 mo vs placebo 11.2 mo; HR = 0.74; p &lt; .0001). CTC counts were evaluated in 972 pts at screening and BL, 838 at 4 wks, 783 at 8 wks and 723 pts at 12 wks. High concordance between screening and BL values was observed (r = 0.83). CTC conversion using standard definition for unfavorable (CTC ≥ 5) and favorable (CTC &lt; 5) counts was predictive of OS as early as 4 wks after treatment and its inclusion significantly reduced the treatment effect at all post-treatment time points (HR: from 0.74 to 0.97). A reduced model incorporating CTCs and LDH was developed. Conclusions: The magnitude of the treatment effect of AA on OS increased with longer FU. Using standard definition of CTC conversion, the biomarker panel demonstrated a level of surrogacy for OS by correlating well with survival and in a model-adjusted analysis dramatically attenuating the treatment effect. BL CTCs and CTC conversion, along with LDH, were key predictors of OS. Future trials will further evaluate the CTC-based surrogate developed from COU-AA-301.
Ability of Early Acting Cytokines to Directly Promote Survival and Suppress Apoptosis of Human Primitive CD34+CD38− Bone Marrow Cells With Multilineage Potential at the Single-Cell Level: Key Role of Thrombopoietin
Authors: Ole J. Borge, Veslemøy Ramsfjell, Li Cui, Sten E.W. Jacobsen
Journal: Blood (1997)
Bioorthogonal Radiopaque Hydrogel for Endoscopic Delivery and Universal Tissue Marking
Authors: Seonki Hong, Jonathan Carlson, Hakho Lee, Ralph Weissleder
Journal: Advanced Healthcare Materials (2015)

A novel dual marking hydrogel system is reported for radiological and laparoscopic localization of lesions. Bioorthogonally crosslinked hydrogel containing both tantalum and India ink can be rapidly formed inside the body after injecting precursors, and stably located for several days as a long-term biocompatible carrier for markers. As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re-organized for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Reply
Authors: Michael Böhm, Michael D. Ezekowitz, Stuart J. Connolly, John W. Eikelboom, Stefan H. Hohnloser, Paul A. Reilly, Helmut Schumacher, Martina Brueckmann, Stephan H. Schirmer, Mario T. Kratz, Salim Yusuf, Hans-Christoph Diener, Ziad Hijazi, Lars Wallentin
Journal: Journal of the American College of Cardiology (2015)
Transcription Factor Hepatocyte Nuclear Factor–1β Regulates Renal Cholesterol Metabolism
Authors: Karam Aboudehen, Min Soo Kim, Matthew Mitsche, Kristina Garland, Norma Anderson, Lama Noureddine, Marco Pontoglio, Vishal Patel, Yang Xie, Russell DeBose-Boyd, Peter Igarashi
Journal: Journal of the American Society of Nephrology (2015)

HNF-1 β is a tissue–specific transcription factor that is expressed in the kidney and other epithelial organs. Humans with mutations in HNF-1β develop kidney cysts, and HNF-1 β regulates the transcription of several cystic disease genes. However, the complete spectrum of HNF-1 β –regulated genes and pathways is not known. Here, using chromatin immunoprecipitation/next generation sequencing and gene expression profiling, we identified 1545 protein-coding genes that are directly regulated by HNF-1 β in murine kidney epithelial cells. Pathway analysis predicted that HNF-1 β regulates cholesterol metabolism. Expression of dominant negative mutant HNF-1 β or kidney-specific inactivation of HNF-1 β decreased the expression of genes that are essential for cholesterol synthesis, including sterol regulatory element binding factor 2 ( Srebf2 ) and 3-hydroxy-3-methylglutaryl-CoA reductase ( Hmgcr ). HNF-1 β mutant cells also expressed lower levels of cholesterol biosynthetic intermediates and had a lower rate of cholesterol synthesis than control cells. Additionally, depletion of cholesterol in the culture medium mitigated the inhibitory effects of mutant HNF-1 β on the proteins encoded by Srebf2 and Hmgcr , and HNF-1 β directly controlled the renal epithelial expression of proprotein convertase subtilisin–like kexin type 9, a key regulator of cholesterol uptake. These findings reveal a novel role of HNF-1 β in a transcriptional network that regulates intrarenal cholesterol metabolism.
Combination Chemotherapy With Carboplatin, Docetaxel, and Gemcitabine in Advanced Non–Small-Cell Lung Cancer: A Phase II Study
Authors: D. Pectasides, A. Aspropotamitis, A. Halikia, A. Visvikis, F. Antoniou, A. Kalantaridou, N. Karvounis, S. Batzios, A. Athanassiou
Journal: Journal of Clinical Oncology (1999)

PURPOSE: To evaluate the efficacy and toxicity of the combination of carboplatin, docetaxel, and gemcitabine in patients with advanced non–small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Forty-five chemotherapy-naive patients with NSCLC were treated on an out-patient basis with carboplatin area under the curve 5 intravenous (IV) and gemcitabine 800 mg/m 2 IV on day 1 and docetaxel 75 mg/m 2 IV and gemcitabine 800 mg/m 2 IV on day 8. Granulocyte colony-stimulating factor (150 ug/m 2 subcutaneously) was given prophylactically from day 3 to day 6 and day 10 to day 16. Chemotherapy was repeated every 4 weeks. Patients were evaluated for response every two cycles of treatment. RESULTS: The median age of the patients was 58 years (range, 24 to 75 years). The performance status was 0 for 16 patients, 1 for 17 patients, and 2 for 12 patients. Nine patients (20%) had stage IIIB disease, and 36 (80%) had stage IV; histology was mainly squamous cell carcinoma (51.2% of patients) that was poorly differentiated (37.8%). All 45 patients were assessable for toxicity, and 41 were assessable for response. On an intent-to-treat analysis, the objective response rate was 46.5% (21 out of 45 patients; 95% confidence interval [CI], 31.7% to 62.5%). Of the 45 patients, four (8.8%) achieved a complete response (95% CI, 2.5% to 21.2%); 17 (37.7%) achieved a partial response (95% CI, 23.8% to 53.5%); seven (15.5%) had stable disease; and 14 (31.1%) had progressive disease. The median survival time was 13.5 months, and the actuarial 1-year survival rate was 51.11%. The median duration of response was 7.6 months, and the time to tumor progression was 8.1 months. Grade 3/4 anemia and thrombocytopenia occurred in 17.7% and 28.8% of patients, respectively. Twenty-one patients (46.6%) developed grade 3/4 neutropenia, and six patients (13.3%) were complicated with fever. Alopecia was universal. Grade 3 diarrhea occurred in four patients (8.8%); grade 3/4 neurotoxicity occurred in 10 patients (22.2%); and grade 2/3 allergic reaction occurred in three patients (16.6%). There were no treatment-related deaths. Six patients (13.3%) required a dose reduction, two of which required two reductions. CONCLUSIONS: The combination of carboplatin, docetaxel, and gemcitabine is an effective regimen for the treatment of chemotherapy-naive patients with advanced NSCLC, causing only moderate toxicity.
Brain targeted delivery of paclitaxel using endogenous ligand
Authors: Sanjeev R. Acharya, Padmanabha R.V. Reddy
Journal: Asian Journal of Pharmaceutical Sciences (2015)

The objective of the present investigation was to formulate nanoparticles constructed using PLGA polymer for the effective targeted delivery to brain via nasal route. The PLGA nanoparticles were optimized using novel design of experiment technique by 23 full factorial design. Drug: polymer ratio (X1), surfactant concentration (X2) and stirring speed (X3) were identified as critical process parameters, and its impact on particle size (Y1) and % entrapment efficiency (Y2) was studied. The optimized nanoparticle formulation was conjugated with glutathione as an endogenous ligand by using carbodiimide chemistry using (1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide) (EDAC) as linker molecule. From Ellman's assay, it was found that a total of 691.27 ± 151 units of glutathione were conjugated upon each PLGA nanoparticle. The in vitro release studies as well as ex vivo studies revealed biphasic pattern of drug release with initial burst release followed by slow exponential release of drug over a period of 24 h. The in vivo biodistribution studies were conducted on rat following nasal administration of the nanoparticle formulation (conjugated and unconjugated) and were compared with plain paclitaxel suspension. The results clearly demonstrated that the brain targeting efficiency was enhanced with the glutathione conjugated formulation (387.474%) as compared to the unconjugated nanoparticle formulation (224.327%). Further, the in vitro in vivo correlation studies revealed good relationship (R2 > 0.95) as obtained from the levy plot. Glutathione proves to be an efficient vector for the successful transport of poor bioavailable drug to the brain.
The Cancer/Testis Antigens of SSX4, MAGE-A3, and CTAG2 Are Attractive Targets for Cancer Immunotherapy in Korean Patients with Multiple Myeloma
Authors: Nu-Ri Choi, Sung-Hoon Jung, Hyun-Ju Lee, Manh-Cuong Vo, My-Dung Hoang, Hyeoung-Joon Kim, Je-Jung Lee
Journal: Blood (2014)
Ex vivo fluorescence confocal microscopy in conjunction with Mohs micrographic surgery for cutaneous squamous cell carcinoma
Authors: Caterina Longo, Moira Ragazzi, Stefano Gardini, Simonetta Piana, Elvira Moscarella, Aimilios Lallas, Margherita Raucci, Giuseppe Argenziano, Giovanni Pellacani
Journal: Journal of the American Academy of Dermatology (2015)
In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer
Authors: Michalina Janiszewska, Lin Liu, Vanessa Almendro, Yanan Kuang, Cloud Paweletz, Rita A Sakr, Britta Weigelt, Ariella B Hanker, Sarat Chandarlapaty, Tari A King, Jorge S Reis-Filho, Carlos L Arteaga, So Yeon Park, Franziska Michor, Kornelia Polyak
Journal: Nature Genetics (2015)
Abstract 17955: Thereapeutic Angiogenesis Induced by Human Trx-1 Gene in Mice Hind Limb Ischemia Model: Preclinical Study for Treatment of Peripheral Artery Disease
Authors: Mahesh Thirunavukkarasu, Inam A Shaikh, Vaithinathan Selvaraju, J.Alexandar Palesty, Nilanjana Maulik
Journal: Circulation (2014)

Introduction: Peripheral artery disease affects 12-20% Americans over the age of 60. Thioredoxin-1 (Trx-1) is a class of small redox proteins. We have demonstrated earlier that Trx-1 reduces oxidative stress resulting in less inflammation and increased angiogenesis in cardiac muscle via heme oxygenase-1 (HO-1) and VEGF after myocardial infarction. In the current study, we evaluate the effect of Trx-1 on post-ischemic hindlimb recovery. Methods: Peripheral artery disease was mimicked using a hindlimb ischemia (HLI) model. Wild type (WT) and Trx-1 transgenic (Trx-1Tg/+) mice (8-12 weeks old) were subjected to femoral artery ligation. Following surgery, mice were observed for 5 weeks. Serial laser doppler images were obtained, and perfusion ratios between the ischemic and non-ischemic limbs were calculated at set time intervals. The perfusion ratios were compared between WT and Trx-1Tg/+ groups. Immunohistochemical analysis of the skeletal muscle was performed to quantify the extent of fibrosis, capillary and arteriolar density 35 days after surgery. In addition, another set of experiments was designed with Ad.Trx-1 gene therapy after femoral artery ligation to study the molecular mechanism of neovascularization with Trx-1. Results: The recovery of hind limb perfusion was significantly increased in Trx-1Tg/+ mice at day 7 (0.19 ± 0.03 vs. 0.36 ± 0.07 (n=12-9), day-21 (0.37 ± 0.05 vs. 0.62 ± 0.03 (n=12-9), and day 28 (0.40 ± 0.04 vs. 0.79 ± 0.04 (n=10-9); p&lt;0.05). Capillary density [1265 ± 87.8 vs. 762.4 ± 86.6 counts/mm2 ; (n=5); p&lt;0.05] and arteriolar density [36.2 ± 2.96 vs. 22± 1.33 counts/mm2 ; (n=5); p&lt;0.05] staining showed significant increase in Trx-1Tg/+ mice as compared to WT mice. Picrosirrus Red and immunofluorescence staining showed decreased fibrosis [8.3 ± 0.46 vs. 22.2 ± 1.04 (n=5); p&lt;0.0001] and increased HO-1 expression respectively in Trx-1Tg/+ mice group as compared to WT mice, respectively. Trx-1 gene therapy study also revealed by Western blot analysis, increased Trx-1 (4.2 fold) and HO-1 (8.2 fold) expression in Ad.Trx-1-HLI as compared to Ad.LacZ-HLI. Conclusions: Our results suggest that Trx-1 is a potential therapeutic agent to increase blood perfusion and angiogenesis for the treatment of critical limb ischemia patients.
Abstract P096: Effectiveness of a Comprehensive Care Delivery System on Readmission Rates and Self-Care in Older Adult Patients with Heart Failure
Authors: Linda L Tavares
Journal: Circulation (2015)

Background: Telemedicine interventions to prevent readmissions in patients with heart failure (HF) have shown inconsistent results in their effectiveness on HF-related and all-cause rehospitalization. Team-based interventions geared toward patient-centric care delivery in concert with comprehensive care coordination that enhances patient self-care may help to prevent unplanned hospitalizations in patients with HF. Objective: To evaluate the outcomes of a comprehensive care delivery system using a team-based high-touch coaching and remote patient monitoring intervention designed for older adult patients with heart failure in a community hospital setting. Design: A descriptive cross-sectional observational design was used to measure readmission rates. A one-group pretest-posttest design using the Self-care of Heart Failure Index was used to measure self-care outcomes. Correlation analysis was performed to determine relationships between the coaching and outcomes. Patients: Participants were older adult patient hospitalized with heart failure and followed for 30-days. Patients were excluded if they were unwilling to participate, non- English speaking, had end-stage renal disease, a terminal illness, debilitating neuro-psychological disorder, or lived greater than 30 miles away. Results: The 30-patients were primarily Caucasian, female with a mean age of 77.5 years. The majority of patients had medically optimized NYHA class II or III HF with an ejection fraction ≤ 40%. HF readmission rate was zero, and 6% for all cause. Patient self-care scores improved (p &lt; .0001). Team based coaching was correlated with improvement in self-care maintenance scores (p =.009). Conclusion: A comprehensive care delivery system leveraging remote patient monitoring and health coaching significantly reduced 30-day readmission and enhanced patient self-care management. Implications: Patient centric team based care models leveraging technology should continue to be developed and implemented to transform care delivery for older adults with HF. Table 1. Change in Mean Self-Care of Heart Failure Index Scores p &lt; .0001 p &lt; .0001 p &lt; .0001